Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Celldex Therapeutics (NQ: CLDX ) 43.86 +4.55 (+11.57%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 25, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Celldex Therapeutics < Previous 1 2 3 4 Next > Analyst Expectations For Celldex Therapeutics's Future July 16, 2024 Via Benzinga Analyst Expectations For Celldex Therapeutics's Future June 03, 2024 Via Benzinga Unveiling 4 Analyst Insights On Celldex Therapeutics May 07, 2024 Via Benzinga CLDX Stock Earnings: Celldex Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 06, 2024 CLDX stock results show that Celldex Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday March 01, 2024 U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday. Via Benzinga Topics Stocks Exposures US Equities Celldex Therapeutics: Q4 Earnings Insights February 26, 2024 Via Benzinga Forecasting The Future: 5 Analyst Projections For Celldex Therapeutics December 20, 2023 Via Benzinga What 7 Analyst Ratings Have To Say About Celldex Therapeutics November 10, 2023 Via Benzinga Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session February 26, 2024 Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. Via Benzinga Celldex Stock Hits 11-Month High, Up 19%, On A Promising New Hives Treatment February 26, 2024 The company tested its treatment in chronic spontaneous urticaria. Almost 38% of patients had "complete control" after 12 weeks. Via Investor's Business Daily Top Picks 2024: Celldex Therapeutics, Inc. January 28, 2024 Celldex Therapeutics is one of our top picks for the year. With very good data and the financing behind it, now could be the time to take advantage of the pullback in shares to initiate and/or add to... Via Talk Markets 4 Analysts Have This to Say About Celldex Therapeutics May 31, 2023 Via Benzinga Celldex Therapeutics: Q1 Earnings Insights May 04, 2023 Via Benzinga Why Celldex Therapeutics Shares Are Trading Higher Today February 27, 2023 Via Benzinga Celldex Therapeutics Earnings Perspective: Return On Capital Employed December 19, 2022 Via Benzinga Top 4 Health Care Stocks That May Crash This Month December 20, 2023 As of Dec. 20, 2023, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. Via Benzinga Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare November 17, 2023 Are you looking for biotech breakthrough stocks? Here are three revolutionary stocks redefining healthcare. Via InvestorPlace Why Celldex Therapeutics (CLDX) Stock Is Getting Hammered November 08, 2023 Celldex Therapeutics, Inc. (NASDAQ: CLDX) shares are trading lower after the company announced a proposed public offering of 7.425 million shares at $27 per share. Via Benzinga Why Celldex Therapeutics Blasted 13% Higher on Monday November 06, 2023 The biotech's CSU treatment advanced in the laboratory. Via The Motley Fool Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi November 06, 2023 The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases. Via Investor's Business Daily Why Is Inflammation Disease-Focused Celldex Therapeutics Stock Trading Higher Today? November 06, 2023 Celldex Therapeutics Inc (NASDAQ: CLDX) released topline results from its Phase 2 trial of barzolvolimab in patients with moderate to severe chronic spontaneous urticaria (CSU) refractory to... Via Benzinga Why Bluegreen Vacations Shares Are Trading Higher By Around 105%? Here Are Other Stocks Moving In Monday's Mid-Day Session November 06, 2023 Gainers Carbon Revolution Public Limited (NASDAQ: CREV) shares jumped 396.2% to $145.49 after gaining 100% on Friday. The company’s stock began trading on Friday following merger with Twin Ridge... Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session November 06, 2023 Via Benzinga Wall Street's Top 10 Stock Calls This Week - Sunday, Aug. 27 August 27, 2023 Via Talk Markets Benzinga's Top Ratings Upgrades, Downgrades For August 22, 2023 August 22, 2023 Via Benzinga A New Era In Regenerative Medicine? BioRestorative Therapies (NASDAQ: BRT) Reports Leading The Expansion Of The Adipose-Derived Stem Cell Therapy Market May 11, 2023 Brown Adipose-Derived Stem Cell (BADSC) therapy has emerged as a groundbreaking innovation in regenerative medicine, capturing the attention of scientists, clinicians and investors alike. Via Benzinga 10 Health Care Stocks With Whale Alerts In Today's Session May 09, 2023 Via Benzinga Union Pacific, Kosmos Energy, Fisker And Other Big Stocks Moving Higher On Monday February 27, 2023 U.S. stocks traded higher, with the Dow Jones gaining more than 300 points on Monday. Here are some big stocks recording gains in today’s session. Via Benzinga These '20 Stocks To Watch' Moved On Last Fed Rate Hike: How Will They React Today? February 01, 2023 The Federal Reserve's interest rate hike announcements have the potential to cause significant volatility in the stock market. Via Benzinga BriaCell’s Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients December 14, 2022 By Ernest Dela Aglanu, Benzinga Via News Direct Topics Death Exposures Death < Previous 1 2 3 4 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.